Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)
Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)
复制标题
同种异体骨髓移植治疗继发性白血病和骨髓增生异常综合征：欧洲骨髓移植组 (EBMTG) 白血病工作组的一项调查
DOI：
--
复制
发表时间：
1990
影响因子：
6.5
通讯作者：
A. Gratwohl
中科院分区：
文献类型：
--
作者：
TM deWitte;A. Ferrant;F. Zwaan;J. Hermans;J. Vernant;H. Kolb;J. Vossen;B. Lönnqvist;D. Beelen;J. Gmür;J. Yin;X. Troussard;J. Cahn;M. Vanlint;A. Gratwohl
This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who received an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the 2‐year disease‐free survival. Thirty‐four patients received intensive chemotherapy prior to the conditioning for BMT. The 2‐year disease‐free survival was 60% for the 16 patients transplanted in complete remission. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (2‐year diseasefree survival: 18%) while none of those who either relapsed or were resistant to chemotherapy survived BMT for 2 years. Forty‐four patients had not received any prior intensive chemotherapy. The disease‐free survival at 2 years after BMT was 58 ± 19% when a patient was transplanted for refractory anaemia (RA(S)), 74 ± 14% for refractory anaemia with excess of blasts (RAEB), 50 ± 16% for RAEB in transformation (RAEBt), and 18 ± 11% for secondary AML.
登录
查看更多内容
霍奇金病治疗后的急性非淋巴细胞白血病的骨髓移植。
DOI：
10.1200/jco.1987.5.5.731
发表时间：
1987
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Sargur,M;Buckner,CD;Appelbaum,FR;Stewart,P;Deeg,HJ;Weiden,PL;Sullivan,KM;Fefer,A;Thomas,ED
通讯作者：
Thomas,ED
骨髓移植治疗骨髓增生异常和骨髓增殖综合征。
DOI：
10.1200/jco.1987.5.11.1822
发表时间：
1987
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
O'Donnell,MR;Nademanee,AP;Snyder,DS;Schmidt,GM;Parker,PM;Bierman,PJ;Fahey,JL;Stein,AS;Krance,RA;Stock,AD
通讯作者：
Stock,AD
霍奇金病治疗后成功进行骨髓移植治疗急性粒细胞白血病。
DOI：
10.1200/jco.1988.6.10.1558
发表时间：
1988
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Geller,RB;Vogelsang,GB;Wingard,JR;Yeager,AM;Burns,WH;Santos,GW;Saral,R
通讯作者：
Saral,R
阿糖胞苷治疗继发性急性非淋巴细胞白血病。
DOI：
10.1056/nejm198301063080105
发表时间：
1983
期刊：
The New England journal of medicine
影响因子：
--
作者：
Preisler,HD;Early,AP;Raza,A;Vlahides,G;Marinello,MJ;Stein,AM;Browman,G
通讯作者：
Browman,G
尽管细胞遗传学对高剂量阿糖胞苷有完全反应，但治疗相关白血病的缓解持续时间较短。
影响因子：
20.3
作者：
Larson,RA;Wernli,M;LeBeau,MM;Daly,KM;Pape,LH;Rowley,JD;Vardiman,JW
通讯作者：
Vardiman,JW